Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Seven RNAi-Related Patent Applications: Jun 21, 2007

Premium
Title: Modified siRNA Molecules and Uses Thereof
 
Numbers: 20070135372
 
Filed: Nov. 2, 2006
 
Lead Inventor: Ian MacLachlan, Protiva Biotherapeutics
 
The invention, the patent application’s abstract states, “provides chemically modified siRNA molecules and methods of using such siRNA molecules to silence target gene expression. Advantageously, the modified siRNA of the present invention is less immunostimulatory than its corresponding unmodified siRNA sequence and retains RNAi activity against the target sequence. The … invention also provides nucleic acid-lipid particles comprising a modified siRNA, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles,” the abstract adds. The invention “further provides methods of silencing gene expression by administering a modified siRNA to a mammalian subject. Methods for identifying and/or modifying an siRNA having immunostimulatory properties are also provided.”
 

 
Title: siRNA Silencing of Filovirus Gene Expression
 
Numbers: 20070135370
 
Filed: Oct. 20, 2006
 
Lead Inventor: Ian MacLachlan, Protiva Biotherapeutics
 
The invention comprises “siRNA molecules that target Filovirus gene expression and methods of using such siRNA molecules to silence Filovirus gene expression,” the patent application’s abstract states. The invention “also provides nucleic acid-lipid particles that target Filovirus gene expression comprising an siRNA that silences Filovirus gene expression, a cationic lipid, and a non-cationic lipid.”
 

 
Title: Cell-to-Cell Transmission of siRNA-Induced Gene Silencing in Mammalian Cells
 
Numbers: 20070135368
 
Filed: Feb. 10, 2006
 
Lead Inventor: Pamela Knapp, University of Kentucky College of Medicine
 
The patent application, its abstract states, claims a “method for reducing expression of a target gene in a mammalian cell. … The method comprises introducing siRNA into a first mammalian cell such that expression of the target gene is reduced in the first mammalian cell, and exposing a second mammalian cell which does not contain siRNA that reduces expression of the target gene to the siRNA-containing first mammalian cell, thereby resulting in reduced expression of the target gene in the second mammalian cell. An additional aspect provides a method of reducing expression of a target gene in a mammal,” it adds. “Yet another aspect provides a mammalian cell transfected with an expression vector which directs expression of siRNA for a target gene such that expression of the target gene is reduced in the transfected mammalian cell, and the siRNA expression level is sufficient to signal reduction of target gene expression in a mammalian cell not transfected with siRNA for the target gene.”
 

 
Title: siRNA Targeting Histamine Receptor H1
 
Numbers: 20070134698
 
Filed: Nov. 9, 2006
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.”
 

 
Title: siRNA Targeting TIE-2
 
Numbers: 20070134697
 
Filed: Nov. 3, 2006
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.”
 

 
Title: Bioinformatically Detectable Group of Novel Regulatory Genes and Uses Thereof
 
Numbers: 20070134655
 
Filed: Nov. 16, 2003 PCT Filed: Nov. 16, 2003
 
Inventor: Isaac Bentwich, Rosetta Genomics
 
The invention, according to the patent application’s abstract, “relates to a first group of novel genes, here identified as genomic address messenger or GAM genes, and a second group of novel operon-like genes, here identified as genomic record or GR genes. GAM genes selectively inhibit translation of known target genes, many of which are known to be involved in various diseases. Nucleic acid molecules are provided respectively encoding 8,607 GAM genes, and 1,096 GR genes, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM and GR genes and specific functions and utilities thereof, for detecting expression of GAM and GR genes, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.”
 

 
Title: Double-Stranded RNA Oligonucleotides Which Inhibit Tyrosinase Expression
 
Numbers: 20070134188
 
Filed: Sept. 21, 2006
 
Lead Inventor: Christine Collin-Djangone, L’Oreal
 
According to the patent application’s abstract, “novel double-stranded RNA oligonucleotides are useful for decreasing tyrosinase expression, have cosmetic and/or pharmaceutical applications, for example are useful skin depigmenting or anti-browning agents, and can be associated with cationic particles less than or equal to 1 [micrometer] in size, having a zeta potential of from 10 to 80 mV.”